WASHINGTON: Johnson & Johnson's COVID-19 vaccine remained in limbo on Wednesday as a U.S. health panel called for more data before making a decision on how and whether to resume use of the one-dose shot, putting off a vote for a week or more.
The U.S. Centers for Disease Control and Prevention (CDC) advisory panel decided to delay a vote on how best to use the J&J shot even after a U.S. Food and Drug Administration scientist told advisers he believed warnings could mitigate the risk of extremely rare but serious blood clots.